"Slingshot represents an opportunity to bridge the gap between academic innovation and clinical development of a novel ...

Syncona Shs GBP (GB:SYNC) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top StocksMake ...

Syncona has launched Slingshot Therapeutics with an initial $15 million investment through its Syncona Accelerator initiative ...

Syncona Shs GBP (GB:SYNC) has released an update. Syncona’s portfolio company, Autolus Therapeutics, has received FDA ...

Syncona Ltd, (“Syncona”) a leading life science investor focused on creating, building and scaling global leaders in life science, today announces that it has launched a new portfolio company ...

Syncona noted that the approval is set against the backdrop of poor outcomes for patients with r/r B-ALL, an aggressive blood ...

(Sharecast News) - Syncona announced the launch of Slingshot Therapeutics, a new portfolio company and accelerator dedicated to developing early-stage life science programs sourced from academia ...

(Alliance News) - Syncona Ltd on Thursday said it launched a new portfolio company as it reported a fall in net asset value, citing a weaker US dollar. The life science investor said net asset ...

Syncona Ltd (SYNC.L) said that its portfolio company Autolus Therapeutics announced that the U.S. Food and Drug Administration has ...

Syncona Shs GBP (GB:SYNC) has released an update. Syncona Limited has repurchased 200,000 of its own shares as part of its ongoing share buyback program, helping to manage its capital structure ...